HCW Biologics Inc. (HCWB) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.24
↓-100% vs avg
5yr avg: 67.55
30Y Low0.7·High131.3
ROE
↓
-287.9%
-6% vs avg
5yr avg: -271.3%
30Y Low-288%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HCWB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
HCW Biologics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $668096 | $2M | $692M | $1.8B | $2.7B | $3.3B | — | — |
| Enterprise Value | $6M | $7M | $701M | $1.8B | $2.7B | $3.3B | — | — |
| P/E Ratio → | -0.03 | — | — | — | — | — | — | — |
| P/S Ratio | 12.32 | 37.56 | 269.62 | 622.05 | 408.15 | — | — | — |
| P/B Ratio | 0.24 | 0.74 | — | 131.32 | 73.30 | 64.84 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HCWB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 127.11 | 273.14 | 623.00 | 405.78 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
HCWB Profitability
Margins and return-on-capital ratios measuring operating efficiency
HCW Biologics Inc. earns an operating margin of -20757.6%. Operating margins have compressed from -905.0% to -20757.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -287.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 20.0% | 20.0% | 37.4% | 19.7% | 38.5% | — | 100.0% | — |
| Operating Margin | -20757.6% | -20757.6% | -1148.5% | -905.0% | -224.3% | — | -142.1% | — |
| Net Profit Margin | -14677.1% | -14677.1% | -1169.7% | -879.5% | -221.7% | — | -141.0% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -287.9% | -287.9% | -897.4% | -98.2% | -33.6% | -39.2% | -49.4% | -81.0% |
| ROA | -29.1% | -29.1% | -102.2% | -66.4% | -29.7% | -37.3% | -45.4% | -72.5% |
| ROIC | -171.1% | -171.1% | -240.1% | -102.4% | -37.1% | -43.6% | -107.2% | — |
| ROCE | -553.9% | -553.9% | -289.4% | -80.8% | -31.7% | -40.8% | -49.8% | -81.8% |
HCWB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $5M ($7M total debt minus $2M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.46 | 2.46 | — | 0.47 | 0.17 | — | 0.04 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.76 | — | 0.20 | -0.43 | -0.23 | -0.55 | -0.82 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -5.37 | -5.37 | -24.92 | -87.31 | -116.64 | — | — | — |
HCWB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.11x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.73x to 0.11x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.11 | 0.11 | 0.19 | 0.73 | 11.52 | 17.44 | 12.14 | 7.53 |
| Quick Ratio | 0.11 | 0.11 | 0.19 | 0.73 | 11.05 | 17.44 | 12.14 | 7.53 |
| Cash Ratio | 0.09 | 0.09 | 0.16 | 0.41 | 10.84 | 15.81 | 8.45 | 6.90 |
| Asset Turnover | — | 0.00 | 0.08 | 0.10 | 0.14 | — | 0.27 | — |
| Inventory Turnover | — | — | — | — | 2.96 | — | — | — |
| Days Sales Outstanding | — | 216.55 | 82.79 | 197.25 | 22.68 | — | 222.57 | — |
HCWB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
HCW Biologics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $2M | $39M | $36M | $36M | $36M | $37M | $37M |
Peer Comparison
Compare HCWB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HCWBYou | $668096 | -0.0 | — | — | 20.0% | -20757.6% | -287.9% | -171.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 XNCR | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See HCWB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HCWB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HCWB vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonHCWB — Frequently Asked Questions
Quick answers to the most common questions about buying HCWB stock.
What is HCW Biologics Inc.'s P/E ratio?
HCW Biologics Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is HCW Biologics Inc.'s ROE?
HCW Biologics Inc.'s return on equity (ROE) is -287.9%. The historical average is -98.2%.
Is HCWB stock overvalued?
Based on historical data, HCW Biologics Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are HCW Biologics Inc.'s profit margins?
HCW Biologics Inc. has 20.0% gross margin and -20757.6% operating margin.